Tag: date

TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, wishes to respond to a misleading press release published earlier today by Apollo Technology Capital Corporation (“Apollo”) prematurely claiming that it considers the results of the annual and special meeting of shareholders scheduled to take place at 3:00 p.m. today (the “Meeting”) to be a clear victory for Apollo.

ATHENS, Greece, June 16, 2025 (GLOBE NEWSWIRE) -- Imperial Petroleum Inc. (Nasdaq: IMPP) (the “Company”), a ship-owning company providing petroleum products, crude oil, and drybulk seaborne transportation services, today announced a dividend of $0.546875 per share on its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Shares”), payable on June 30, 2025 to holders of record as of June 25, 2025. The dividend payment relates to the period from the last dividend payment date for the Series A Preferred Shares on March 30, 2025, through June 29, 2025.

COMMUNIQUÉ

Article 14(1) of the Law of 2 May 2007 on the disclosure of large shareholders in issuers whose shares are admitted to trading on a regulated market

NEW HAVEN, Conn., June 16, 2025 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today, no later than 11 pm Eastern Time.

Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 56,416 Ageas shares in the period from 09-06-2025 until 13-06-2025.

Chicago, Illinois, June 16, 2025 (GLOBE NEWSWIRE) -- Mag Mile Capital, Inc. (OTCQB: MMCP) ("Mag Mile", or the "Company") is pleased to announce the successful arrangement of $10.25 million in joint venture equity on behalf of the development team executing an innovative Class A office-to-multifamily conversion project at 111 W. Illinois in the River North neighborhood of Chicago, IL.

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis.

MONTREAL, June 16, 2025 (GLOBE NEWSWIRE) -- Boralex inc. (“Boralex” or the “Company”) (TSX: BLX) announces that its 2030 Strategy will be presented at an Investor Day on June 17, 2025, from 10 a.m. to 12:30 p.m., in Toronto.

MONTRÉAL, 16 juin 2025 (GLOBE NEWSWIRE) -- Boralex inc. (« Boralex » ou la « Société ») (TSX : BLX) annonce que sa Stratégie 2030 sera présenté dans le cadre d’une Journée de l’investisseur le 17 juin 2025, de 10 h à 12 h 30, à Toronto.